<DOC>
	<DOCNO>NCT01232712</DOCNO>
	<brief_summary>The scientific approach behind study develop novel anti-cancer therapeutic vaccine induce robust cellular immune response mediate via CD4+ CD8+ T lymphocytes population applicable majority target population .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy MUC1 Peptide Vaccine hGM-CSF Patients With MUC1-positive Tumor Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . All* patient must histological cytological diagnosis metastatic disease hematological malignancy express MUC1 . Patients must metastatic disease , fail least one regimen standard base chemotherapy metastatic disease indicate follow table . Patients must disease consider incurable surgical radiological intervention . 2 . Patients must &gt; 18 year age , consent participate study . 3 . Patients must least one site measurable tumor measurable tumor marker . 4 . Radiological relevant imaging study , CT scan , must perform within 4 week first treatment baseline document extent disease . 5 . Patients least 4 week beyond major surgery chemoradiotherapy recover drug induce toxicity . 6 . Patients must performance status 70 % great Karnofsky scale ( ECOG 02 ) minimal life expectancy 12 month . 7 . Patients must sign informed consent , mentally responsible . In Multiple Myeloma , MUC1 expression test confirm inclusion/exclusion criterion meet within screen period . 1 . Patients fulfil criterion . 2 . Patients significant concurrent medical complication judgment Principal Investigator could affect patient 's ability tolerate complete study . 3 . Patients receive immunosuppressive treatment could negate development effective immune response vaccine . ( First vaccination least 30 day end immunosuppressive treatment ) 4 . Subjects prior irradiation field include 25 % lymph node bone marrow likely immunosuppressed exclude . However , patient standard pelvic field radiation adjuvant therapy rectal cancer exclude . 5 . Pregnant breast feed woman exclude . Premenopausal woman practice willing practice adequate birth control method period 3 month treatment exclude . 6 . Patients brain metastasis . 7 . Patients active infection . 8 . Patients HIV HBSAg HCV positive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>MUC1</keyword>
	<keyword>ImMucin</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>